Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Ticagrelor vs. Clopidogrel in Stable CAD Patients Undergoing Elective PCI
NCT06228456Phase 4Recruiting
- Sponsor
- University of Florida
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in coronary artery disease (CAD) (2 arms), sponsored by University of Florida. Primary endpoint: P2Y12 reaction units at 30 days. Started Apr 2024; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06228456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06228456.